Oxymatrine Plus Lamivudine Combination Therapy Versus Lamivudine Monotherapy for Chronic Hepatitis B Infected Subjects

NCT02202473 Phase 4 COMPLETED

The purpose of this study is to evaluate the efficacy of Oxymatrine plus Lamivudine Combination Therapy and whether it could lower the incidence of Lamivudine long-term resistance compared to Lamivudine Monotherapy.

Details

Lead sponsor	Southeast University, China
Phase	Phase 4
Status	COMPLETED
Enrolment	192

Conditions

• Chronic Hepatitis B

Interventions

• Lamivudine
• Lamivudine+Oxymatrine Capsules

Primary outcomes

• Reduction of Hepatitis B virus DNA titer compared to Baseline Hepatitis B virus DNA titer every 3 months for 18 months — 1, 3, 6, 12, 15, 18 months

Countries

China